Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Clin Breast Cancer. 2017 Apr 26;17(5):382–391. doi: 10.1016/j.clbc.2017.04.009

Table 1.

Clinicopathologic characteristics of MBC and TNBC cases.

Variables TNBC (n=508) MBC (n=46) P-value
Age (years) Median (range) 57(25,91) 54.5(42,90) 0.51
Race African American 95(94.1)* 6(5.9) 0.637
Others 12(92.3) 1(7.7)
Caucasian 401(91.1) 39(8.9)
Tumor Size(cm) Median(range) 1.7(0.2,13) 3.1(0.5,14) <0.001
T-stage 1 317(95.8) 14(4.2) <0.001
2 160(88.9) 20(11.1)
3 28(73.7) 10(26.3)
4 3(60.0) 2(40.0)
No. positive nodes Median (range) 0(0,32) 0(0,14) 0.486
N-stage Negative 340(91.4) 32(8.6) 0.622
Positive 168(92.8) 13(7.2)
Stage I 242(95.3) 12(4.7) 0.014
II 201(88.2) 27(11.8)
III 65(90.3) 7(9.7)
Nottingham Grade 1 5(100.0) 0(0.0) 0.064
2 47(100.0) 0(0.0)
3 456(90.8) 46(9.2)
Surgery Lumpectomy 351(95.4) 17(4.6) <0.001
Mastectomy 157(84.4) 29(15.6)
Neoadjuvant No 439(92.4) 36(7.6) 0.128
Yes 69(87.3) 10(12.7)
Radiation Therapy No 100(84.0) 19(16.0) 0.002
Yes 403(93.7) 27(6.3)
Chemotherapy No 119(96.8) 4(3.2) 0.024
Yes 386(90.4) 41(9.6)
*

N(%);

MBC Metaplastic breast cancer, TNBC Triple negative breast cancer